Druck Icon

Eckert & Ziegler Invests in a New Production Line

(Ad hoc press release)

Berlin, 20.07.2000. Eckert & Ziegler Strahlen- und Medizintechnik AG, an innovative developer of radioactive components for the treatment of cancer and restenosis, and Californian-based Radiance Medical Systems Inc. have agreed to add substantial production capacity for a new medical restenosis prevention device at Eckert & Ziegler's Berlin facility. In an agreement executed Wednesday, both companies decided to jointly invest, during the next 12 months up to one million Euro into a new production lines for cardio-vascular components. At the same time both parties will intensify their cooperation in the investigation of process improvements. The new production line has the potential to increase Eckert & Ziegler's annual revenue volume by several million Euro. Further to increases in production capacity, Eckert & Ziegler also decided to intensify its development efforts for second generation cardio-vasular brachytherapy products. "The recent undisputed approval by an FDA advisory board of the Cordis cardio-vascular brachytherapy system, which Eckert & Ziegler manufactures, has excited patients and doctors. It reminded everyone of the efficacy of brachytherapy in preventing restenosis", explained Dr. Andreas Eckert, President and CEO of Eckert & Ziegler AG. "We recently were able to secure a major European medical device manufacturer as a development ally and now want to strengthen our lead through further investments in this area".

The Board of Directors